CA2959832A1 - Methods for detecting ovarian cancer - Google Patents
Methods for detecting ovarian cancer Download PDFInfo
- Publication number
- CA2959832A1 CA2959832A1 CA2959832A CA2959832A CA2959832A1 CA 2959832 A1 CA2959832 A1 CA 2959832A1 CA 2959832 A CA2959832 A CA 2959832A CA 2959832 A CA2959832 A CA 2959832A CA 2959832 A1 CA2959832 A1 CA 2959832A1
- Authority
- CA
- Canada
- Prior art keywords
- small molecule
- concentration
- ovarian cancer
- acid
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 151
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title claims description 63
- 238000004393 prognosis Methods 0.000 claims abstract description 16
- 239000000090 biomarker Substances 0.000 claims description 165
- 150000003384 small molecules Chemical class 0.000 claims description 147
- 206010028980 Neoplasm Diseases 0.000 claims description 79
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical group CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 65
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 61
- 102100023123 Mucin-16 Human genes 0.000 claims description 61
- 239000000523 sample Substances 0.000 claims description 58
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- 230000004083 survival effect Effects 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 26
- 239000002207 metabolite Substances 0.000 claims description 25
- 239000013068 control sample Substances 0.000 claims description 24
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 23
- 239000001361 adipic acid Substances 0.000 claims description 22
- 235000011037 adipic acid Nutrition 0.000 claims description 21
- 150000002576 ketones Chemical class 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- DZAIOXUZHHTJKN-UHFFFAOYSA-N 3,4-dihydroxybutyric acid Chemical compound OCC(O)CC(O)=O DZAIOXUZHHTJKN-UHFFFAOYSA-N 0.000 claims description 15
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical class CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 11
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 claims description 10
- DFGRBDTXILTPTO-UHFFFAOYSA-N 2,2,3-trihydroxybutanoic acid Chemical compound CC(O)C(O)(O)C(O)=O DFGRBDTXILTPTO-UHFFFAOYSA-N 0.000 claims description 10
- KYICBZWZQPCUMO-PSALXKTOSA-N N-myristoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](COP([O-])(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCC KYICBZWZQPCUMO-PSALXKTOSA-N 0.000 claims description 10
- 150000001261 hydroxy acids Chemical class 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- DLVZBSZXZDGKQY-UHFFFAOYSA-N 2,2-dihydroxybutanoic acid Chemical class CCC(O)(O)C(O)=O DLVZBSZXZDGKQY-UHFFFAOYSA-N 0.000 claims description 9
- LOUGYXZSURQALL-UHFFFAOYSA-N 2,3-dihydroxybutanoic acid Chemical compound CC(O)C(O)C(O)=O LOUGYXZSURQALL-UHFFFAOYSA-N 0.000 claims description 9
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 claims description 9
- YXSZOBWVQJIWNE-QVDCKBILSA-N N-heneicosanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC YXSZOBWVQJIWNE-QVDCKBILSA-N 0.000 claims description 9
- 238000005481 NMR spectroscopy Methods 0.000 claims description 9
- UFYGCFHQAXXBCF-UHFFFAOYSA-N 2,4-dihydroxybutanoic acid Chemical compound OCCC(O)C(O)=O UFYGCFHQAXXBCF-UHFFFAOYSA-N 0.000 claims description 8
- 230000002611 ovarian Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- QEDPUVGSSDPBMD-XTAIVQBESA-N N-lignoceroylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC QEDPUVGSSDPBMD-XTAIVQBESA-N 0.000 claims description 7
- SXZWBNWTCVLZJN-NMIJJABPSA-N N-tricosanoylsphing-4-enine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC SXZWBNWTCVLZJN-NMIJJABPSA-N 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 238000011275 oncology therapy Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 230000037356 lipid metabolism Effects 0.000 claims description 4
- 238000007398 colorimetric assay Methods 0.000 claims description 2
- 238000010387 dual polarisation interferometry Methods 0.000 claims description 2
- 238000007824 enzymatic assay Methods 0.000 claims description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 claims description 2
- 238000007421 fluorometric assay Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000000101 novel biomarker Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 49
- 210000001519 tissue Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 20
- 230000009467 reduction Effects 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000107 tumor biomarker Substances 0.000 description 12
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000012474 protein marker Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- JPIJQSOTBSSVTP-UHFFFAOYSA-N 2,3,4-trihydroxybutanoic acid Chemical compound OCC(O)C(O)C(O)=O JPIJQSOTBSSVTP-UHFFFAOYSA-N 0.000 description 5
- AZQSINYIKQSHFR-UHFFFAOYSA-N 4,4,4-trihydroxybutanoic acid Chemical class OC(=O)CCC(O)(O)O AZQSINYIKQSHFR-UHFFFAOYSA-N 0.000 description 5
- VBFKEZGCUWHGSK-ADSSWVSQSA-N N-[(13Z)-docosenoyl]sphing-4-enine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](COP([O-])(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VBFKEZGCUWHGSK-ADSSWVSQSA-N 0.000 description 5
- FBFWDBGUSMGXPI-UHFFFAOYSA-N TG(17:0/17:0/17:0) Chemical compound CCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCC FBFWDBGUSMGXPI-UHFFFAOYSA-N 0.000 description 5
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- MDRFMTLYKHBJTF-NQYLGBTJSA-N N-(11Z-icosenoyl)-sphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](COP([O-])(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCC\C=C/CCCCCCCC MDRFMTLYKHBJTF-NQYLGBTJSA-N 0.000 description 4
- FJJANLYCZUNFSE-TWKUQIQBSA-N N-docosanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC FJJANLYCZUNFSE-TWKUQIQBSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 150000002190 fatty acyls Chemical group 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 239000012855 volatile organic compound Substances 0.000 description 4
- YSFFAUPDXKTJMR-DIPNUNPCSA-N 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCC YSFFAUPDXKTJMR-DIPNUNPCSA-N 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- -1 MG(17:0/0:0/0:0) Chemical compound 0.000 description 3
- ICWGMOFDULMCFL-QKSCFGQVSA-N N-heptadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC ICWGMOFDULMCFL-QKSCFGQVSA-N 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000002366 time-of-flight method Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-M 3,4-dihydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1O YQUVCSBJEUQKSH-UHFFFAOYSA-M 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- KZSNJWFQEVHDMF-RGZIBPOXSA-N Valine-d8 Chemical compound [2H]CC([2H])(C([2H])([2H])[2H])[C@]([2H])(N([2H])[2H])C(O)=O KZSNJWFQEVHDMF-RGZIBPOXSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000091 biomarker candidate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-LNLMKGTHSA-N succinic acid-d4 Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])C(O)=O KDYFGRWQOYBRFD-LNLMKGTHSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- YXLMNFVUNLCJJY-UHFFFAOYSA-N 1-bromo-4-(4-bromo-2,3,5,6-tetrafluorophenyl)-2,3,5,6-tetrafluorobenzene Chemical group FC1=C(Br)C(F)=C(F)C(C=2C(=C(F)C(Br)=C(F)C=2F)F)=C1F YXLMNFVUNLCJJY-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- 101100423701 Arabidopsis thaliana OVA1 gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100086716 Caenorhabditis elegans ran-3 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- ZBVHXVKEMAIWQQ-QPPIDDCLSA-N PG(17:0/17:0) Chemical compound CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCC ZBVHXVKEMAIWQQ-QPPIDDCLSA-N 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- 241001596784 Pegasus Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 238000012352 Spearman correlation analysis Methods 0.000 description 1
- RGROBSGNJZWWRZ-DHUJRADRSA-N [(2s)-2-heptadecanoyloxy-3-hydroxypropyl] heptadecanoate Chemical compound CCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCCC RGROBSGNJZWWRZ-DHUJRADRSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VHYWECIJXTVRSG-TVDLSCFRSA-N cholesteryl nonadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCCC)C1 VHYWECIJXTVRSG-TVDLSCFRSA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012615 high-resolution technique Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000001285 laser absorption spectroscopy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20145855 | 2014-10-02 | ||
| FI20145855 | 2014-10-02 | ||
| PCT/FI2015/050654 WO2016051020A1 (en) | 2014-10-02 | 2015-10-02 | Methods for detecting ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2959832A1 true CA2959832A1 (en) | 2016-04-07 |
Family
ID=55629471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2959832A Abandoned CA2959832A1 (en) | 2014-10-02 | 2015-10-02 | Methods for detecting ovarian cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10534001B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3201623B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6892820B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170061704A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106716127B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015326756A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017006593A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2959832A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201701875YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016051020A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351938A1 (en) * | 2017-01-18 | 2018-07-25 | BIOCRATES Life Sciences AG | New biomarkers for assessing ovarian cancer |
| WO2019008009A1 (en) | 2017-07-05 | 2019-01-10 | Zora Biosciences Oy | METHODS OF DETECTING OVARIAN CANCER |
| CN107656006A (zh) * | 2017-09-08 | 2018-02-02 | 上海市东方医院 | 用于检测血清或者血浆中α‑羟基丁酸浓度的试剂盒和方法 |
| CN108152430A (zh) * | 2017-12-21 | 2018-06-12 | 上海中科新生命生物科技有限公司 | 基于prm检测的卵巢癌标志物检测试剂盒及检测方法 |
| WO2020160108A1 (en) * | 2019-01-30 | 2020-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Lipid biomarkers for cancer screening and monitoring |
| CN111430030A (zh) * | 2020-04-17 | 2020-07-17 | 武汉大学 | 生物标志物在卵巢癌评估中的应用方法及系统 |
| CN114544848B (zh) * | 2020-11-25 | 2023-04-28 | 中国科学院大连化学物理研究所 | 一种用于诊断卵巢上皮癌的血清脂质标志物组合物及试剂盒和其与应用 |
| EP4246146A1 (en) * | 2022-03-14 | 2023-09-20 | Fundació Institut Mar d'Investigacions Mèdiques (IMIM) | Method for diagnosing cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824555A (en) | 1996-05-30 | 1998-10-20 | The Cleveland Clinic Foundation | Method of detecting gynecological carcinomas |
| US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
| US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
| US20040199819A1 (en) * | 2001-08-10 | 2004-10-07 | Jorg Dauerer | Method for fast and local error correction in the event of the failure of individual physical corrections in bundled communication connections and communication system device for carrying out the method |
| US20040180387A1 (en) * | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
| US20050170441A1 (en) | 2003-09-12 | 2005-08-04 | Health Research, Inc. | Early detection of cancer of specific type using 1HNMR metabonomics |
| WO2009052186A1 (en) * | 2007-10-15 | 2009-04-23 | Georgia Tech Research Corporation | Metabolomics-based identification of disease-causing agents |
| US9213030B2 (en) | 2008-01-28 | 2015-12-15 | National University Of Singapore | Lipid tumour profile |
| WO2009151967A1 (en) | 2008-05-28 | 2009-12-17 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
| JP4744618B2 (ja) * | 2009-04-13 | 2011-08-10 | シャープ株式会社 | ガス成分検出装置 |
| KR20120011042A (ko) * | 2009-04-15 | 2012-02-06 | 샌포드-번햄 메디칼 리서치 인스티튜트 | 항아폽토시스 단백질의 나프탈렌계 억제제 |
| EP2513653A1 (en) * | 2009-10-09 | 2012-10-24 | Carolyn Slupsky | Methods for diagnosis, treatment and monitoring of patient health using metabolomics |
| US20110114511A1 (en) * | 2009-11-17 | 2011-05-19 | Sjong Angele | Apparatus for detecting volatile organic compounds and related methods |
| GB201016139D0 (en) | 2010-09-24 | 2010-11-10 | Univ Leuven Kath | Cancer phosholipidome |
| FI20115576A0 (fi) * | 2011-06-10 | 2011-06-10 | Teknologian Tutkimuskeskus Vtt Oy | Menetelmä Alzheimerin taudin diagnoimiseksi |
| US20140156573A1 (en) | 2011-07-27 | 2014-06-05 | The Research Foundation Of State University Of New York | Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc |
-
2015
- 2015-10-02 CN CN201580052938.0A patent/CN106716127B/zh active Active
- 2015-10-02 SG SG11201701875YA patent/SG11201701875YA/en unknown
- 2015-10-02 US US15/513,755 patent/US10534001B2/en active Active
- 2015-10-02 BR BR112017006593A patent/BR112017006593A2/pt not_active Application Discontinuation
- 2015-10-02 CA CA2959832A patent/CA2959832A1/en not_active Abandoned
- 2015-10-02 AU AU2015326756A patent/AU2015326756A1/en not_active Abandoned
- 2015-10-02 WO PCT/FI2015/050654 patent/WO2016051020A1/en not_active Ceased
- 2015-10-02 KR KR1020177011691A patent/KR20170061704A/ko not_active Withdrawn
- 2015-10-02 JP JP2017516994A patent/JP6892820B2/ja active Active
- 2015-10-02 EP EP15846140.0A patent/EP3201623B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015326756A1 (en) | 2017-05-11 |
| CN106716127B (zh) | 2020-12-08 |
| EP3201623A4 (en) | 2018-07-25 |
| EP3201623A1 (en) | 2017-08-09 |
| KR20170061704A (ko) | 2017-06-05 |
| EP3201623B1 (en) | 2020-07-22 |
| JP6892820B2 (ja) | 2021-06-23 |
| US20170285036A1 (en) | 2017-10-05 |
| JP2017535756A (ja) | 2017-11-30 |
| SG11201701875YA (en) | 2017-04-27 |
| WO2016051020A1 (en) | 2016-04-07 |
| BR112017006593A2 (pt) | 2017-12-19 |
| CN106716127A (zh) | 2017-05-24 |
| US10534001B2 (en) | 2020-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3201623B1 (en) | Methods for detecting ovarian cancer | |
| Murgia et al. | Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels | |
| AU2017201020B2 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| Del Boccio et al. | Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis | |
| CA2799032A1 (en) | Methods to diagnose liver diseases | |
| Li et al. | Metabolomic profiling of plasma samples from women with recurrent spontaneous abortion | |
| US8758992B2 (en) | Method for the differential diagnosis of non-alcoholic fatty liver disease based on a metabolomic profile | |
| AU2014217452B2 (en) | Means and methods for assessing the quality of a biological sample | |
| Wasinger et al. | Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: a quantitative proteomic perspective | |
| Yi et al. | Metabolomic identification of novel biomarkers of nasopharyngeal carcinoma | |
| Issaq et al. | Biomarker discovery: study design and execution | |
| Recber et al. | Optimization and normalization strategies for long term untargeted HILIC-LC-qTOF-MS based metabolomics analysis: Early diagnosis of breast cancer | |
| CA2525740A1 (en) | Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer | |
| Kuukkanen et al. | UHPLC-MS/MS-based untargeted metabolite profiling of Lyme neuroborreliosis | |
| US20210405054A1 (en) | Methods for detecting ovarian cancer | |
| Rakhshan et al. | Applications of mass spectroscopy in understanding cancer proteomics | |
| King | Addressing the analytical challenges of metabolomic studies: Increasing the throughput and reducing the complexity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20211223 |
|
| FZDE | Discontinued |
Effective date: 20211223 |